18.73
+0.73(+4.06%)
Currency In USD
| Previous Close | 18 |
| Open | 18.06 |
| Day High | 18.75 |
| Day Low | 17.81 |
| 52-Week High | 53.08 |
| 52-Week Low | 17.37 |
| Volume | 449,340 |
| Average Volume | 728,693 |
| Market Cap | 1.29B |
| PE | -3.91 |
| EPS | -4.79 |
| Moving Average 50 Days | 24.68 |
| Moving Average 200 Days | 28.72 |
| Change | 0.73 |
If you invested $1000 in Arvinas, Inc. (ARVN) since IPO date, it would be worth $1,166.98 as of December 26, 2024 at a share price of $18.73. Whereas If you bought $1000 worth of Arvinas, Inc. (ARVN) shares 5 years ago, it would be worth $422.04 as of December 26, 2024 at a share price of $18.73.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Arvinas and Pfizer Announce Initial Phase 1b Data from the TACTIVE-U Sub-Study of Vepdegestrant in Combination with Abemaciclib at 2024 San Antonio Breast Cancer Symposium
GlobeNewswire Inc.
Dec 10, 2024 2:05 PM GMT
– Vepdegestrant in combination with abemaciclib demonstrated encouraging clinical activity (clinical benefit rate: 62.5%; overall response rate: 26.7%) in patients previously treated with a CDK4/6 inhibitor – – Safety and tolerability of the combinat
Arvinas to Present at Piper Sandler 36th Annual Healthcare Conference
GlobeNewswire Inc.
Nov 27, 2024 12:00 PM GMT
NEW HAVEN, Conn., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Noah Berkowitz, M.D., Ph.D., Chief Me
Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 San Antonio Breast Cancer Symposium
GlobeNewswire Inc.
Nov 25, 2024 10:35 PM GMT
NEW HAVEN, Conn., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today announced that three posters for vepdegestrant, including clinical data, will be presented at the 2024 San Antonio Breast Cancer Symposium (SABCS), being held De